Silencing of p130Cas in ovarian carcinoma: A novel mechanism for tumor cell death

Journal of the National Cancer Institute

Volumn 103, Issue 21, 2011, Pages 1596-1612

  Nick, Alpa M ^a   Stone, Rebecca L ^a   Armaiz Pena, Guillermo ^b   Ozpolat, Bulent ^b   Tekedereli, Ibrahim ^b   Graybill, Whitney S ^a   Landen, Charles N ^d   Villares, Gabriel ^b   Vivas Mejia, Pablo ^b,e   Bottsford Miller, Justin ^a   Kim, Hye Sun ^b   Lee, Ju Seog ^b   Kim, Soo Mi ^c   Baggerly, Keith A ^b   Ram, Prahlad T ^b   Deavers, Michael T ^b   Coleman, Robert L ^a   Lopez Berestein, Gabriel ^a,b   Sood, Anil K ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Department of Cancer Biology ^*  (United States)

^c Chonbuk National University Medical School   (South Korea)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; DIOLEOYLPHOSPHATIDYLCHOLINE; DNA NUCLEOTIDYLEXOTRANSFERASE; DOCETAXEL; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ASCITES; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER STAGING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISTANT METASTASIS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO GENE TRANSFER; INTRACELLULAR SIGNALING; LIPOSOMAL GENE DELIVERY SYSTEM; MOUSE; NICK END LABELING; NONHUMAN; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT RESPONSE;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CARCINOMA; CELL SURVIVAL; CRK-ASSOCIATED SUBSTRATE PROTEIN; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MEMBRANE PROTEINS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAXOIDS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 80655144781     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr372     Document Type: Article

References (66)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96. (Pubitemid 351521864)
2. Hogdall E. Cancer antigen 125 and prognosis. Curr Opin Obstet Gynecol. 2008;20(1):4-8.
3. Bast RCJr, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15(suppl 3):274-281. (Pubitemid 43096594)
4. Jacobs I, Stablile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet. 1988;1(8580):268-271. (Pubitemid 18052262)
5. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402-408. (Pubitemid 351174295)
6. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG. 2005;112(7):857-865. (Pubitemid 40896949)
7. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194-3200. (Pubitemid 46606249)
8. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1-6. (Pubitemid 26012496)
9. Bookman MA. Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol. 2003;21(10 suppl):149s-167s.
10. Burger RA, Sill MW, Monk BJ, Greer BE, Soroski JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171. (Pubitemid 350237599)
11. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180-5186. (Pubitemid 350232248)
12. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601-5606.
13. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-2519.
14. Sakai R, Iwamatsu A, Hirano N, et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J. 1994;13(16):3748-3756. (Pubitemid 24275020)
15. Defilippi P, Di Stefano P, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 2006;16(5):257-263. (Pubitemid 43728873)
16. Brabek J, Constancio SS, Siesser PF, Shin NY, Pozzi A, Hank SK. Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells. Mol Cancer Res. 2005;3(6):307-315. (Pubitemid 40905622)
17. Panetti TS. Tyrosine phosphorylation of paxillin, FAK, and p130CAS: effects on cell spreading and migration. Front Biosci. 2002;7:2143-2150.
18. Sanders MA, Basson MD. p130cas but not paxillin is essential for Caco-2 intestinal epithelial cell spreading and migration on collagen IV. J Biol Chem. 2005;280(25):23516-23522. (Pubitemid 40884829)
19. Chodniewicz D, Klemke RL. Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold. Biochim Biophys Acta. 2004;1692(2-3):63-76. (Pubitemid 38891768)
20. O'Neill GM, Fashena SJ, Golemis EA. Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol. 2000;10(3):111-119. (Pubitemid 30110694)
21. Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol. 1998;140(4):961-972. (Pubitemid 28141232)
22. Shim SR, Kook S, Kim JI, Song WK. Degradation of focal adhesion proteins paxillin and p130cas by caspases or calpains in apoptotic rat-1 and L929 cells. Biochem Biophys Res Commun. 2001;286(3):601-608. (Pubitemid 32912989)
23. Kim W, Kook S, Kim DJ, Teodorof C, Song WK. The 31-kDa caspase-generated cleavage product of p130cas functions as a transcriptional repressor of E2A in apoptotic cells. J Biol Chem. 2004;279(9):8333-8342. (Pubitemid 38294725)
24. Wei L, Yang Y, Zhang X, Yu Q. Cleavage of p130Cas in anoikis. J Cell Biochem. 2004;91(2):325-335.
25. Cabodi S, Tinnirello A, Di Stefano P, et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res. 2006;66(9):4672-4680.
26. Ambrogio C, Voena C, Manazza AD, et al. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005;106(12):3907-3916. (Pubitemid 41739031)
27. Honda H, Oda H, Nakamoto T, et al. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet. 1998;19(4):361-365. (Pubitemid 28357908)
28. Tazaki T, Miyazaki K, Hiyama E, et al. Functional analysis of Src homology 3-encoding exon (exon 2) of p130Cas in primary fibroblasts derived from exon 2-specific knockout mice. Genes Cells. 2008;13(2):145-157. (Pubitemid 351188985)
29. Fromont G, Vallancien G, Validire P, Levillain P, Cussenot O. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. Prostate. 2007;67(3):268-273.
30. Dorssers LC, Grebenchtchikov N, Brinkman A, et al. The prognostic value of BCAR1 in patients with primary breast cancer. Clin Cancer Res. 2004;10(18, pt 1):6194-6202. (Pubitemid 39287526)
31. Grebenchtchikov N, Brinkman A, van Broekhoven SP, et al. Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue. Clin Chem. 2004;50(8):1356-1363. (Pubitemid 38970642)
32. Dorssers LC, Grebenchtchikov N, Brinkman A, et al. Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer. Clin Chem. 2004;50(8):1445-1447. (Pubitemid 38970662)
33. van der Flier S, Brinkman A, Look MP, et al. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst. 2000;92(2):120-127. (Pubitemid 30089868)
34. Nasertorabi F, Garcia-Guzman M, Briknarova K, et al. Organization of functional domains in the docking protein p130Cas. Biochem Biophys Res Commun. 2004;324(3):993-998. (Pubitemid 39361606)
35. Patwardhan P, Shen Y, Goldberg GS, Miller WT. Individual Cas phosphorylation sites are dispensable for processive phosphorylation by Src and anchorage-independent cell growth. J Biol Chem. 2006;281(30):20689-20697. (Pubitemid 44115411)
36. Ohmori T, Yatomi Y, Inoue K, Satoh K, Ozaki Y. Tyrosine dephosphorylation, but not phosphorylation, of p130Cas is dependent on integrin alpha IIb beta 3-mediated aggregation in platelets: implication of p130Cas involvement in pathways unrelated to cytoskeletal reorganization. Biochemistry. 2000;39(19):5797-5807. (Pubitemid 30307968)
37. Wisniewska M, Bossenmaier B, Georges G, et al. The 1.1 A resolution crystal structure of the p130cas SH3 domain and ramifications for ligand selectivity. J Mol Biol. 2005;347(5):1005-1014. (Pubitemid 40387448)
38. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939-944. (Pubitemid 44175146)
39. Landen CNJr, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65(15):6910-6918. (Pubitemid 41060730)
40. Halder J, Kamat AA, Landen CNJr, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006;12(16):4916-4924. (Pubitemid 44338579)
41. Hwang JY, Mangala LS, Fok JY, et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res. 2008;68(14):5849-5858.
42. Thaker PH, Yazici S, Nilsson MB, et al. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res. 2005;11(13):4923-4933. (Pubitemid 41557213)
43. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ. A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett. 1987;38(1-2):137-147. (Pubitemid 18005844)
44. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI (Translated from English). Nucleic Acids Res. 2007;35(Database issue):D26-D31. (Pubitemid 46056164)
45. Bader G. BIND-The biomolecular interaction network database (Translated from English). Nucleic Acids Res. 2001;29(1):242-245. (Pubitemid 32054459)
46. Kanehisa M, Goto S KEGG: kyoto encyclopedia of genes and genomes (Translated from English). Nucleic Acids Res. 2000;28(1):27-30. (Pubitemid 30047706)
47. Griffith O. ORegAnno: an open-access community-driven resource for regulator annontation (Translated from English). Nucleic Acids Res. 2008;36(D):107-113.
48. Ashburner M. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. (Translated from English). Nat Genet. 2000;25(1):25-29.
49. Lovasz L. Random walks on graphs: a survey. Bolyayu Soc Math Stud. 1993;2(2):1-46.
50. Akar U, Chaves-Reyez A, Barria M, et al. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008;4(5):669-679.
51. Klionsky DJ, Abellovich H, Agostinis P, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4(2):151-175. (Pubitemid 351231180)
52. Hoskins W, Perez C, Young R. Principles and Practice of Gynecologic Oncology. Riverwoods, IL: Lippincott Williams & Wilkins; 2005.
53. Van der Burg ME. Advanced ovarian cancer. Curr Treat Options Oncol. 2001;2(2):109-118.
54. Bouchard VJ, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol. 2003;31(6):446-454. (Pubitemid 36793950)
55. Levine B, Sinha S, Kroemer G. Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy. 2008;4(5):600-606.
56. Tan ML, Ooi JP, Ismail N, Moad AI, Muhammad TS. Programmed cell death pathways and current antitumor targets. Pharm Res. 2009;26(7):1547-1560.
57. Zouq NK, Keeble JA, Lindsay J, et al. FAK engages multiple pathways to maintain survival of fibroblasts and epithelia: differential roles for paxillin and p130Cas. J Cell Sci. 2009;122(pt 3):357-367.
58. Nasertorabi F, Alonso A, Rogers SW, et al. Crystallization of the SH2-binding site of p130Cas in complex with Lck, a Src-family kinase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005;61(pt 2):174-177. (Pubitemid 44210940)
59. Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. 2006;5(12):1708-1713.
60. Kook S, Shim SR, Choi SJ, et al. Caspase-mediated cleavage of p130cas in etoposide-induced apoptotic Rat-1 cells. Mol Biol Cell. 2000;11(3):929-939. (Pubitemid 30159312)
61. Ta HQ, Thomas KS, Schrecengost RS, Bouton AH. A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells. Cancer Res. 2008;68(21):8796-8804.
62. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther. 2009;8(21):2084-2096.
63. Xue L, Fletcher GC, Tolkovsky AM. Autophagy is activated by apoptotic signalling in sympathetic neurons: an alternative mechanism of death execution. Mol Cell Neurosci. 1999;14(3):180-198. (Pubitemid 29449222)
64. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene. 2004;23(16):2891-2906. (Pubitemid 38638851)
65. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res. 2003;63(9):2103-2108. (Pubitemid 36538613)
66. Xue L, Fletcher GC, Tolkovsky AM. Mitochondria are selectively eliminated from eukaryotic cells after blockade of caspases during apoptosis. Curr Biol. 2001;11(5):361-365. (Pubitemid 32200740)